Cargando…

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

BACKGROUND: RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the potential of different oligonucleotide-based strategies for silencing the genes respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiszer, Agnieszka, Olejniczak, Marta, Switonski, Pawel M, Wroblewska, Joanna P, Wisniewska-Kruk, Joanna, Mykowska, Agnieszka, Krzyzosiak, Wlodzimierz J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359213/
https://www.ncbi.nlm.nih.gov/pubmed/22397573
http://dx.doi.org/10.1186/1471-2199-13-6
_version_ 1782233836839501824
author Fiszer, Agnieszka
Olejniczak, Marta
Switonski, Pawel M
Wroblewska, Joanna P
Wisniewska-Kruk, Joanna
Mykowska, Agnieszka
Krzyzosiak, Wlodzimierz J
author_facet Fiszer, Agnieszka
Olejniczak, Marta
Switonski, Pawel M
Wroblewska, Joanna P
Wisniewska-Kruk, Joanna
Mykowska, Agnieszka
Krzyzosiak, Wlodzimierz J
author_sort Fiszer, Agnieszka
collection PubMed
description BACKGROUND: RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the potential of different oligonucleotide-based strategies for silencing the genes responsible for several polyQ diseases, including Huntington's disease and two spinocerebellar ataxias, type 1 and type 3. The strategies included nonallele-selective gene silencing, gene replacement, allele-selective SNP targeting and CAG repeat targeting. RESULTS: Using the patient-derived cell culture models of polyQ diseases, we tested various siRNAs, and antisense reagents and assessed their silencing efficiency and allele selectivity. We showed considerable allele discrimination by several SNP targeting siRNAs based on a weak G-G or G-U pairing with normal allele and strong G-C pairing with mutant allele at the site of RISC-induced cleavage. Among the CAG repeat targeting reagents the strongest allele discrimination is achieved by miRNA-like functioning reagents that bind to their targets and inhibit their translation without substantial target cleavage. Also, morpholino analog performs well in mutant and normal allele discrimination but its efficient delivery to cells at low effective concentration still remains a challenge. CONCLUSIONS: Using three cellular models of polyQ diseases and the same experimental setup we directly compared the performance of different oligonucleotide-based treatment strategies that are currently under development. Based on the results obtained by us and others we discussed the advantages and drawbacks of these strategies considering them from several different perspectives. The strategy aimed at nonallele-selective inhibiting of causative gene expression by targeting specific sequence of the implicated gene is the easiest to implement but relevant benefits are still uncertain. The gene replacement strategy that combines the nonallele-selective gene silencing with the expression of the exogenous normal allele is a logical extension of the former and it deserves to be explored further. Both allele-selective RNAi approaches challenge cellular RNA interference machinery to show its ability to discriminate between similar sequences differing in either single base substitutions or repeated sequence length. Although both approaches perform well in allele discrimination most of our efforts are focused on repeat targeting due to its potentially higher universality.
format Online
Article
Text
id pubmed-3359213
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33592132012-05-24 An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases Fiszer, Agnieszka Olejniczak, Marta Switonski, Pawel M Wroblewska, Joanna P Wisniewska-Kruk, Joanna Mykowska, Agnieszka Krzyzosiak, Wlodzimierz J BMC Mol Biol Research Article BACKGROUND: RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the potential of different oligonucleotide-based strategies for silencing the genes responsible for several polyQ diseases, including Huntington's disease and two spinocerebellar ataxias, type 1 and type 3. The strategies included nonallele-selective gene silencing, gene replacement, allele-selective SNP targeting and CAG repeat targeting. RESULTS: Using the patient-derived cell culture models of polyQ diseases, we tested various siRNAs, and antisense reagents and assessed their silencing efficiency and allele selectivity. We showed considerable allele discrimination by several SNP targeting siRNAs based on a weak G-G or G-U pairing with normal allele and strong G-C pairing with mutant allele at the site of RISC-induced cleavage. Among the CAG repeat targeting reagents the strongest allele discrimination is achieved by miRNA-like functioning reagents that bind to their targets and inhibit their translation without substantial target cleavage. Also, morpholino analog performs well in mutant and normal allele discrimination but its efficient delivery to cells at low effective concentration still remains a challenge. CONCLUSIONS: Using three cellular models of polyQ diseases and the same experimental setup we directly compared the performance of different oligonucleotide-based treatment strategies that are currently under development. Based on the results obtained by us and others we discussed the advantages and drawbacks of these strategies considering them from several different perspectives. The strategy aimed at nonallele-selective inhibiting of causative gene expression by targeting specific sequence of the implicated gene is the easiest to implement but relevant benefits are still uncertain. The gene replacement strategy that combines the nonallele-selective gene silencing with the expression of the exogenous normal allele is a logical extension of the former and it deserves to be explored further. Both allele-selective RNAi approaches challenge cellular RNA interference machinery to show its ability to discriminate between similar sequences differing in either single base substitutions or repeated sequence length. Although both approaches perform well in allele discrimination most of our efforts are focused on repeat targeting due to its potentially higher universality. BioMed Central 2012-03-07 /pmc/articles/PMC3359213/ /pubmed/22397573 http://dx.doi.org/10.1186/1471-2199-13-6 Text en Copyright ©2012 Fiszer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fiszer, Agnieszka
Olejniczak, Marta
Switonski, Pawel M
Wroblewska, Joanna P
Wisniewska-Kruk, Joanna
Mykowska, Agnieszka
Krzyzosiak, Wlodzimierz J
An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
title An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
title_full An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
title_fullStr An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
title_full_unstemmed An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
title_short An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases
title_sort evaluation of oligonucleotide-based therapeutic strategies for polyq diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359213/
https://www.ncbi.nlm.nih.gov/pubmed/22397573
http://dx.doi.org/10.1186/1471-2199-13-6
work_keys_str_mv AT fiszeragnieszka anevaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT olejniczakmarta anevaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT switonskipawelm anevaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT wroblewskajoannap anevaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT wisniewskakrukjoanna anevaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT mykowskaagnieszka anevaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT krzyzosiakwlodzimierzj anevaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT fiszeragnieszka evaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT olejniczakmarta evaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT switonskipawelm evaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT wroblewskajoannap evaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT wisniewskakrukjoanna evaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT mykowskaagnieszka evaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases
AT krzyzosiakwlodzimierzj evaluationofoligonucleotidebasedtherapeuticstrategiesforpolyqdiseases